… most common adverse events with gefitinib. … EGFR mutations for 228 patients in the TRIBUTE
trial. In patients receiving chemotherapy plus erlotinib, the presence of an EGFR mutation …

… Gefitinib and erlotinib, commonly considered as the standard of care in NSCLC patients
harboring EGFR activating mutations… carrying EGFR mutations, and treated with erlotinib, low …

… Resistance to the EGFR TKIs erlotinib and gefitinib, and the … of EGFR TKIs and research
and development of mutation-… the subject of less common EGFR mutations and their clinical …

… this common malignancy is treated. Three generations of EGFR TKIs are now approved for
use in EGFR mutation… with afatinib than gefitinib or erlotinib in patients with uncommon EGFR …

… treatment that targets EGFR mutations known to be less sensitive to erlotinib and gefitinib.
Patients … (table 2), 76 (79%) of whom had one of the common mutations (L858R in exon 21 or …

… -TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has
shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). Osimertinib is …

… mutations in EGFR seem to be particularly sensitive to EGFR … the benefits of gefitinib or
erlotinib in EGFR mutant NSCLC, … the IC 50 for gefitinib against the five most common exon 19 …

… kinase inhibitor (TKI) therapy with erlotinib, gefinitib, or afatinib. However, resistance to the
… Although EGFR C797S mutations are the most commonly detected, other EGFR mutations …

… specific EGFR mutations and their differing clinical impact in patients treated with EGFR-TKIs. …
form of IC 50 values for afatinib, erlotinib and gefitinib against EGFR-wt, L858R- and Del19-…

… to a higher EGFR-dependence of the tumor owing to common … EGFR mutations to gefitinib
or erlotinib showed that two types of uncommon EGFR mutations, namely point mutations in …